Novellia Secures $18M Series A to Scale Patient-Powered Data Platform, Solving Pharma's $50B Problem

Novellia, a pioneering company in the realm of patient data management, has successfully raised $18 million in a Series A funding round led by Spark Capital, with additional investments from Khosla Ventures, Acrew Capital, Bling Capital, and TMV. This latest round brings Novellia's total funding to $28 million as of June 2, 2026. The capital will be primarily allocated to scaling Novellia's AI-powered technology, which empowers patients to access and organize their health histories, a significant advancement in the healthcare data landscape.

Founded with the mission to centralize patient-contributed data for medical research, Novellia addresses a critical gap in the current healthcare data ecosystem, which is often reliant on fragmented datasets from insurance claims and hospital records. This traditional approach not only incurs substantial costs—over $50 billion annually—but also fails to capture the complete patient experience. Novellia’s platform allows patients to unify their medical records from various healthcare providers, thus providing a more comprehensive view of their health history. This capability is particularly beneficial for patients with complex medical conditions who face challenges in managing their health information.

The funding comes at a pivotal time for Novellia, as the company has recently signed several seven-figure contracts with major pharmaceutical firms. These agreements underscore the growing recognition of the value of real-world data in drug development and the need for more patient-centric approaches in research. By leveraging its technology, Novellia not only enhances the efficiency of data collection but also ensures that the insights derived from patient data are actionable and relevant to pharmaceutical companies. This shift towards patient-consented data is expected to transform the landscape of medical research and development.

The healthcare sector is increasingly moving towards solutions that prioritize patient engagement and data transparency. With nearly 70% of patients expressing a willingness to share their health data for research, the demand for platforms that provide control and privacy is on the rise. Novellia's innovative approach addresses this demand by creating a new category of patient-consented data that is both comprehensive and actionable. The company’s proprietary AI technology enables patients to quickly access up to 20 years of medical data, significantly reducing the administrative burden often faced by those with serious health conditions.

Looking ahead, Novellia's successful funding round and strategic partnerships position it well within the rapidly evolving healthcare data landscape. As the industry continues to recognize the importance of real-world evidence in drug development, Novellia's model may serve as a blueprint for future innovations in patient data management. The implications of this funding extend beyond Novellia itself, potentially influencing how pharmaceutical companies approach research and development, ultimately leading to more effective treatments and improved patient outcomes.